CY1115525T1 - Συνθεση και χρηση αντι-αντιστροφων φωσφοροθειοϊκων αναλογων της καλυπτρας αγγελιοφορου rna - Google Patents

Συνθεση και χρηση αντι-αντιστροφων φωσφοροθειοϊκων αναλογων της καλυπτρας αγγελιοφορου rna

Info

Publication number
CY1115525T1
CY1115525T1 CY20141100718T CY141100718T CY1115525T1 CY 1115525 T1 CY1115525 T1 CY 1115525T1 CY 20141100718 T CY20141100718 T CY 20141100718T CY 141100718 T CY141100718 T CY 141100718T CY 1115525 T1 CY1115525 T1 CY 1115525T1
Authority
CY
Cyprus
Prior art keywords
analogs
reverse
arcas
cap
arca
Prior art date
Application number
CY20141100718T
Other languages
English (en)
Inventor
Jacek Jemielity
Ewa M Grudzien-Nogalska
Joanna Kowalska
Edward Darzynkiewicz
Robert E Rhoads
Original Assignee
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College filed Critical Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College
Publication of CY1115525T1 publication Critical patent/CY1115525T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Αποκαλύπτονται νέα ανάλογα καλύπτρας RNA (RNA cap) που περιέχουν μία ή περισσότερες ομάδες φωσφοροθειοϊκών. Τα ανάλογα περιέχουν επίσης τροποποιήσεις στην θέση 2'-Ο 7-μεθυλογουανοσίνης οι οποίες αποτρέπουν την ενσωμάτωση τους με αντίστροφο προσανατολισμό κατά την διάρκεια σύνθεσης mRNA in vitro και γι' αυτό τα ανάλογα είναι "αντι-αντίστροφα ανάλογα καλύπτρας" (ARCAs: anti-reverse cap analogs). Η τροποποίηση ARCA εξασφαλίζει την ακριβή τοποθέτηση του ατόμου S εντός των ενεργών θέσεων πρωτεϊνών δεσμευόμενων με καλύπτρα τόσο στο σύστημα μετάφρασης όσο και στο σύστημα αφαίρεσης καλύπτρας. Τα νέα ανάλογα S-ARCA είναι ανθεκτικά σε ένζυμα αφαίρεσης καλύπτρας in vivo. Μερικά S-ARCAs έχουν υψηλότερη συγγένεια για eIF4E απ' ότι τα αντίστοιχα ανάλογα που δεν περιέχουν ομάδα φωσφοροθειοϊκού. Όταν mRNAs που περιέχουν τα διάφορα S-ARCAs εισάγονται σε καλλιεργημένα κύτταρα, μερικά μεταφράζονται έως και πέντε φορές αποδοτικότερα από mRNAs που συντίθενται με το συμβατικό ανάλογο m7GpppG.
CY20141100718T 2007-06-19 2014-09-08 Συνθεση και χρηση αντι-αντιστροφων φωσφοροθειοϊκων αναλογων της καλυπτρας αγγελιοφορου rna CY1115525T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94484207P 2007-06-19 2007-06-19
EP08771474.7A EP2167523B1 (en) 2007-06-19 2008-06-19 Synthesis and use of anti-reverse phosphorothioate analogs of the messenger rna cap

Publications (1)

Publication Number Publication Date
CY1115525T1 true CY1115525T1 (el) 2017-01-04

Family

ID=40156965

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100718T CY1115525T1 (el) 2007-06-19 2014-09-08 Συνθεση και χρηση αντι-αντιστροφων φωσφοροθειοϊκων αναλογων της καλυπτρας αγγελιοφορου rna

Country Status (15)

Country Link
US (1) US8153773B2 (el)
EP (1) EP2167523B1 (el)
CN (3) CN107501370B (el)
AU (1) AU2008265683B2 (el)
CA (1) CA2692906C (el)
CY (1) CY1115525T1 (el)
DK (1) DK2167523T3 (el)
EA (1) EA017740B1 (el)
ES (1) ES2500515T3 (el)
HK (1) HK1200461A1 (el)
HR (1) HRP20140771T1 (el)
PL (1) PL2167523T3 (el)
PT (1) PT2167523E (el)
SI (1) SI2167523T1 (el)
WO (1) WO2008157688A2 (el)

Families Citing this family (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8304529B2 (en) * 2006-07-28 2012-11-06 Life Technologies Corporation Dinucleotide MRNA cap analogs
WO2009058911A2 (en) * 2007-10-31 2009-05-07 Applied Biosystems Inc. Preparation and isolation of 5' capped mrna
EP2281579A1 (en) * 2009-08-05 2011-02-09 BioNTech AG Vaccine composition comprising 5'-Cap modified RNA
CN101671669B (zh) * 2009-08-27 2012-05-02 浙江大学 一种肝癌靶向性基因表达元件ae及其应用
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
CN104531812A (zh) 2010-10-01 2015-04-22 现代治疗公司 设计核酸及其使用方法
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
ES2911677T3 (es) 2011-10-03 2022-05-20 Modernatx Inc Nucleósidos, nucleótidos y ácidos nucleicos modificados, y sus usos
RS63244B1 (sr) 2011-12-16 2022-06-30 Modernatx Inc Kompozicije modifikovane mrna
CA2865011C (en) 2012-02-29 2021-06-15 Sangamo Biosciences, Inc. Methods and compositions for treating huntington's disease
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US20140010861A1 (en) 2012-04-02 2014-01-09 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
LT2922554T (lt) 2012-11-26 2022-06-27 Modernatx, Inc. Terminaliai modifikuota rnr
WO2014130955A1 (en) 2013-02-25 2014-08-28 Sangamo Biosciences, Inc. Methods and compositions for enhancing nuclease-mediated gene disruption
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
EP3068905A4 (en) 2013-11-11 2017-07-05 Sangamo BioSciences, Inc. Methods and compositions for treating huntington's disease
PT3492593T (pt) 2013-11-13 2021-10-18 Childrens Medical Center Regulação da expressão de genes mediada por nucleases
CN105940013B (zh) 2013-12-09 2020-03-27 桑格摩生物科学股份有限公司 用于治疗血友病的方法和组合物
EP3540060A1 (en) 2013-12-30 2019-09-18 CureVac AG Methods for rna analysis
SG10201805660WA (en) 2013-12-30 2018-08-30 Curevac Ag Methods for rna analysis
SI3102673T1 (sl) 2014-02-03 2020-11-30 Sangamo Therapeutics, Inc. Postopki in sestavki za zdravljenje beta talasemije
EP3929279A1 (en) 2014-03-18 2021-12-29 Sangamo Therapeutics, Inc. Methods and compositions for regulation of zinc finger protein expression
US9522936B2 (en) 2014-04-24 2016-12-20 Sangamo Biosciences, Inc. Engineered transcription activator like effector (TALE) proteins
CN106413760B (zh) 2014-05-08 2020-01-14 桑格摩生物科学股份有限公司 用于治疗亨廷顿病的方法和组合物
WO2015175642A2 (en) 2014-05-13 2015-11-19 Sangamo Biosciences, Inc. Methods and compositions for prevention or treatment of a disease
EP3152319A4 (en) 2014-06-05 2017-12-27 Sangamo BioSciences, Inc. Methods and compositions for nuclease design
JP6748579B2 (ja) 2014-06-10 2020-09-02 キュアバック リアル エステート ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｒｎａ生成を強化する方法及び手段
WO2016014837A1 (en) 2014-07-25 2016-01-28 Sangamo Biosciences, Inc. Gene editing for hiv gene therapy
WO2016019144A2 (en) 2014-07-30 2016-02-04 Sangamo Biosciences, Inc. Gene correction of scid-related genes in hematopoietic stem and progenitor cells
US10889834B2 (en) 2014-12-15 2021-01-12 Sangamo Therapeutics, Inc. Methods and compositions for enhancing targeted transgene integration
EP3274454B1 (en) 2015-03-25 2021-08-25 Editas Medicine, Inc. Crispr/cas-related methods, compositions and components
EP4335918A3 (en) 2015-04-03 2024-04-17 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of b-cells
ES2746340T3 (es) 2015-04-22 2020-03-05 Curevac Ag Composición que contiene ARN para el tratamiento de enfermedades tumorales
JP7030522B2 (ja) 2015-05-11 2022-03-07 エディタス・メディシン、インコーポレイテッド 幹細胞における遺伝子編集のための最適化ｃｒｉｓｐｒ／ｃａｓ９システムおよび方法
AU2016262521A1 (en) 2015-05-11 2017-12-14 Editas Medicine, Inc. CRISPR/CAS-related methods and compositions for treating HIV infection and AIDS
MX2017014446A (es) 2015-05-12 2018-06-13 Sangamo Therapeutics Inc Regulacion de expresion genica mediada por nucleasa.
US10760070B2 (en) 2015-05-29 2020-09-01 Curevac Real Estate Gmbh Method for producing and purifying RNA, comprising at least one step of tangential flow filtration
CA2986262A1 (en) 2015-06-09 2016-12-15 Editas Medicine, Inc. Crispr/cas-related methods and compositions for improving transplantation
US9957501B2 (en) 2015-06-18 2018-05-01 Sangamo Therapeutics, Inc. Nuclease-mediated regulation of gene expression
EP4239080A3 (en) 2015-07-01 2023-11-01 CureVac Manufacturing GmbH Method for analysis of an rna molecule
CN117025590A (zh) 2015-09-21 2023-11-10 垂林克生物技术有限公司 用于合成5’-加帽rna的组合物和方法
IL258030B (en) 2015-09-23 2022-08-01 Sangamo Therapeutics Inc Htt suppressing factors and their uses
DK3362461T3 (da) 2015-10-16 2022-05-09 Modernatx Inc Mrna-cap-analoger med modificeret phosphatbinding
US11866754B2 (en) 2015-10-16 2024-01-09 Modernatx, Inc. Trinucleotide mRNA cap analogs
CA3001351A1 (en) 2015-10-21 2017-04-27 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating hepatitis b virus
EP3368670A1 (en) 2015-10-30 2018-09-05 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating herpes simplex virus
EP3380622A4 (en) 2015-11-23 2019-08-07 Sangamo Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODIFYING IMMUNITY
BR112018012235A2 (pt) 2015-12-18 2018-12-04 Sangamo Therapeutics Inc rompimento alvejado do receptor de células de mhc
CA3008413A1 (en) 2015-12-18 2017-06-22 Sangamo Therapeutics, Inc. Targeted disruption of the t cell receptor
WO2017109161A1 (en) 2015-12-23 2017-06-29 Curevac Ag Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
PL415967A1 (pl) 2016-01-29 2017-07-31 Univ Warszawski 5'-tiofosforanowe analogi końca 5' mRNA (kapu), sposób ich otrzymywania i zastosowanie
WO2017140345A1 (en) 2016-02-15 2017-08-24 Curevac Ag Method for analyzing by-products of rna in vitro transcription
US11920174B2 (en) 2016-03-03 2024-03-05 CureVac SE RNA analysis by total hydrolysis and quantification of released nucleosides
WO2017162266A1 (en) 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Rna replicon for versatile and efficient gene expression
WO2017162265A1 (en) 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Trans-replicating rna
PT3445850T (pt) 2016-04-22 2021-12-06 BioNTech SE Métodos para proporcionar arn de cadeia simples
US20210162037A1 (en) 2016-05-04 2021-06-03 Curevac Ag Influenza mrna vaccines
US20180126003A1 (en) * 2016-05-04 2018-05-10 Curevac Ag New targets for rna therapeutics
WO2017191264A1 (en) 2016-05-04 2017-11-09 Curevac Ag Nucleic acid molecules and uses thereof
MA44869A (fr) 2016-05-06 2019-03-13 Editas Medicine Inc Cellules génétiquement modifiées et leurs procédés de fabrication
AU2017295720B2 (en) 2016-07-13 2021-07-22 Vertex Pharmaceuticals Incorporated Methods, compositions and kits for increasing genome editing efficiency
MX2019001920A (es) 2016-08-19 2019-07-01 Curevac Ag Arn la terapia contra el cancer.
SG10201913948PA (en) 2016-08-24 2020-03-30 Sangamo Therapeutics Inc Engineered target specific nucleases
PE20190568A1 (es) 2016-08-24 2019-04-22 Sangamo Therapeutics Inc Regulacion de la expresion genica usando nucleasas modificadas
WO2018075736A1 (en) 2016-10-20 2018-04-26 Sangamo Therapeutics, Inc. Methods and compositions for the treatment of fabry disease
WO2018078053A1 (en) 2016-10-26 2018-05-03 Curevac Ag Lipid nanoparticle mrna vaccines
CA3041668A1 (en) 2016-10-31 2018-05-03 Sangamo Therapeutics, Inc. Gene correction of scid-related genes in hematopoietic stem and progenitor cells
WO2018102665A1 (en) 2016-12-01 2018-06-07 Sangamo Therapeutics, Inc. Tau modulators and methods and compositions for delivery thereof
US11524066B2 (en) 2016-12-23 2022-12-13 CureVac SE Henipavirus vaccine
US11141476B2 (en) 2016-12-23 2021-10-12 Curevac Ag MERS coronavirus vaccine
JP2020508056A (ja) 2017-02-22 2020-03-19 クリスパー・セラピューティクス・アクチェンゲゼルシャフトＣＲＩＳＰＲ Ｔｈｅｒａｐｅｕｔｉｃｓ ＡＧ 遺伝子編集のための組成物および方法
CA3061612A1 (en) 2017-04-28 2018-11-01 Acuitas Therapeutics, Inc. Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
RU2019139045A (ru) 2017-05-03 2021-06-03 Сангамо Терапьютикс, Инк. Способы и композиции для модификации гена регулятора трансмембранной проводимости при кистозном фиброзе (cftr)
US11512287B2 (en) 2017-06-16 2022-11-29 Sangamo Therapeutics, Inc. Targeted disruption of T cell and/or HLA receptors
CA3066932A1 (en) 2017-07-04 2019-01-10 Curevac Ag Novel nucleic acid molecules
WO2019038332A1 (en) 2017-08-22 2019-02-28 Curevac Ag VACCINE AGAINST BUNYAVIRUS
AU2018333503A1 (en) 2017-09-13 2020-02-27 BioNTech SE RNA replicon for reprogramming somatic cells
CA3074919A1 (en) 2017-09-13 2019-03-21 Biontech Cell & Gene Therapies Gmbh Rna replicon for expressing a t cell receptor or an artificial t cell receptor
AU2018333498B2 (en) 2017-09-13 2023-05-18 BioNTech SE Method of enhancing RNA expression in a cell
EP3707271A1 (en) 2017-11-08 2020-09-16 CureVac AG Rna sequence adaptation
CA3079748A1 (en) 2017-11-09 2019-05-16 Sangamo Therapeutics, Inc. Genetic modification of cytokine inducible sh2-containing protein (cish) gene
EP3723796A1 (en) 2017-12-13 2020-10-21 CureVac AG Flavivirus vaccine
WO2019122371A1 (en) 2017-12-21 2019-06-27 Curevac Ag Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna
US20200361877A1 (en) 2018-01-17 2020-11-19 Vertex Pharmaceuticals Incorporated Quinoxalinone compounds, compositions, methods, and kits for increasing genome editing efficiency
AU2019209290B2 (en) 2018-01-17 2024-03-07 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
BR112020014315A2 (pt) 2018-01-17 2020-12-08 Vertex Pharmaceuticals Incorporated Inibidores de dna-pk
BR112020026125A8 (pt) * 2018-03-15 2022-10-18 Biontech Rna Pharmaceuticals Gmbh Compostos oligonucleotídeos superiores ou 5'-cap- trinucleotídeo e seus usos na estabilização de rna, expressão de proteínas e em terapia
US20210361761A1 (en) 2018-04-05 2021-11-25 Curevac Ag Novel yellow fever nucleic acid molecules for vaccination
MX2020010941A (es) 2018-04-17 2021-01-29 Curevac Ag Moleculas y composiciones novedosas de arn de vsr para vacunacion.
US11690921B2 (en) 2018-05-18 2023-07-04 Sangamo Therapeutics, Inc. Delivery of target specific nucleases
US20210260178A1 (en) 2018-06-27 2021-08-26 Curevac Ag Novel lassa virus rna molecules and compositions for vaccination
JP2022500052A (ja) 2018-09-18 2022-01-04 サンガモ セラピューティクス， インコーポレイテッド プログラム細胞死１（ｐｄ１）特異的ヌクレアーゼ
EP3899034A1 (en) 2018-12-21 2021-10-27 CureVac AG Methods for rna analysis
CN113453707A (zh) 2018-12-21 2021-09-28 库瑞瓦格股份公司 用于疟疾疫苗的rna
WO2020146805A1 (en) 2019-01-11 2020-07-16 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
CA3124837A1 (en) 2019-01-14 2020-07-23 Genentech, Inc. Methods of treating cancer with a pd-1 axis binding antagonist and an rna vaccine
US20220133908A1 (en) 2019-02-08 2022-05-05 Curevac Ag Coding rna administered into the suprachoroidal space in the treatment of ophthalmic diseases
CN113766921A (zh) 2019-04-23 2021-12-07 桑格摩生物治疗股份有限公司 染色体9开放阅读框72基因表达的调节物及其用途
US20220313813A1 (en) 2019-06-18 2022-10-06 Curevac Ag Rotavirus mrna vaccine
AU2020328855A1 (en) 2019-08-14 2022-03-03 CureVac SE RNA combinations and compositions with decreased immunostimulatory properties
BR112022011803A2 (pt) 2019-12-20 2022-08-30 Curevac Ag Nanopartículas de lipídio para entrega de ácidos nucleicos
CN115397459A (zh) 2020-01-31 2022-11-25 基因泰克公司 用pd-1轴结合拮抗剂和rna疫苗诱导新表位特异性t细胞的方法
US11576966B2 (en) 2020-02-04 2023-02-14 CureVac SE Coronavirus vaccine
DE202021004130U1 (de) 2020-02-04 2022-10-26 Curevac Ag Coronavirus-Vakzine
CN115811986A (zh) * 2020-04-22 2023-03-17 生物技术欧洲股份公司 冠状病毒疫苗
BR112022024248A2 (pt) 2020-05-29 2023-10-10 CureVac SE Vacinas de combinação à base de ácido nucleico
WO2021245090A1 (en) 2020-06-04 2021-12-09 BioNTech SE Rna replicon for versatile and efficient gene expression
CA3189338A1 (en) 2020-07-16 2022-01-20 Acuitas Therapeutics, Inc. Cationic lipids for use in lipid nanoparticles
EP4172194A1 (en) 2020-07-31 2023-05-03 CureVac SE Nucleic acid encoded antibody mixtures
CN113234778A (zh) * 2020-08-20 2021-08-10 深圳市瑞吉生物科技有限公司 一种Cap2结构5′帽子类似物及其制备方法和应用
EP4204545A2 (en) 2020-08-25 2023-07-05 Kite Pharma, Inc. T cells with improved functionality
US20240066114A1 (en) 2020-08-31 2024-02-29 CureVac SE Multivalent nucleic acid based coronavirus vaccines
JP2023540134A (ja) 2020-09-08 2023-09-21 ジェネンテック， インコーポレイテッド 蠕動式ポンプおよび減衰装置を使用して薬学的組成物を生産するためのシステムおよび方法
EP4259161A1 (en) 2020-12-09 2023-10-18 BioNTech SE Rna manufacturing
WO2022137133A1 (en) 2020-12-22 2022-06-30 Curevac Ag Rna vaccine against sars-cov-2 variants
JP2024502210A (ja) 2020-12-22 2024-01-17 キュアバック エスイー ＳＡＲＳ－ＣｏＶ－２バリアントに対するＲＮＡワクチン
WO2022135993A2 (en) 2020-12-22 2022-06-30 Curevac Ag Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
WO2022162027A2 (en) 2021-01-27 2022-08-04 Curevac Ag Method of reducing the immunostimulatory properties of in vitro transcribed rna
CN117377491A (zh) 2021-03-26 2024-01-09 葛兰素史克生物有限公司 免疫原性组合物
EP4312988A2 (en) 2021-03-31 2024-02-07 CureVac SE Syringes containing pharmaceutical compositions comprising rna
EP4334446A1 (en) 2021-05-03 2024-03-13 CureVac SE Improved nucleic acid sequence for cell type specific expression
AU2022270658A1 (en) 2021-05-04 2023-11-16 BioNTech SE Technologies for early detection of variants of interest
WO2023006920A1 (en) 2021-07-29 2023-02-02 BioNTech SE Compositions and methods for treatment of melanoma
EP4377331A2 (en) 2021-07-30 2024-06-05 CureVac SE Mrnas for treatment or prophylaxis of liver diseases
CA3230031A1 (en) 2021-09-03 2023-03-09 Patrick Baumhof Novel lipid nanoparticles for delivery of nucleic acids
AU2022336664A1 (en) 2021-09-03 2024-01-18 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
CN113957108A (zh) * 2021-09-09 2022-01-21 上海兆维科技发展有限公司 一种加帽rna的合成方法以及加帽rna转录反应液
CA3234396A1 (en) 2021-10-18 2023-04-27 BioNTech SE Modified replicable rna and related compositions and their use
WO2023066874A1 (en) 2021-10-18 2023-04-27 BioNTech SE Methods for determining mutations for increasing modified replicable rna function and related compositions and their use
WO2023138786A1 (en) 2022-01-21 2023-07-27 BioNTech SE Analysis of rna molecules using catalytic nucleic acids
WO2023144330A1 (en) 2022-01-28 2023-08-03 CureVac SE Nucleic acid encoded transcription factor inhibitors
WO2023166425A1 (en) 2022-03-01 2023-09-07 Crispr Therapeutics Ag Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions
TW202403046A (zh) 2022-03-21 2024-01-16 瑞士商Ｃｒｉｓｐｒ治療公司 用於治療脂蛋白相關的疾病之方法及組成物
WO2023213378A1 (en) 2022-05-02 2023-11-09 BioNTech SE Replicon compositions and methods of using same for the treatment of diseases
WO2023227608A1 (en) 2022-05-25 2023-11-30 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
WO2023237726A1 (en) 2022-06-10 2023-12-14 Pantarhei Oncology B.V. An intracellular tumor-specific variant of human zona pellucida glycoprotein 3 and nucleic acids coding therefor for use in the treatment of cancer
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
CN114941018B (zh) * 2022-06-28 2023-09-22 翌圣生物科技(上海)股份有限公司 cap1帽类似物的合成方法
WO2024017479A1 (en) 2022-07-21 2024-01-25 BioNTech SE Multifunctional cells transiently expressing an immune receptor and one or more cytokines, their use and methods for their production
WO2024056856A1 (en) 2022-09-15 2024-03-21 BioNTech SE Systems and compositions comprising trans-amplifying rna vectors with mirna
WO2024068545A1 (en) 2022-09-26 2024-04-04 Glaxosmithkline Biologicals Sa Influenza virus vaccines
US20240156949A1 (en) 2022-10-28 2024-05-16 Glaxosmithkline Biologicals Sa Nucleic Acid Based Vaccine
GB202404607D0 (en) 2024-03-29 2024-05-15 Glaxosmithkline Biologicals Sa RNA formulation

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4854610A (en) * 1988-02-10 1989-08-08 Bertek, Inc. Method of making laminated articles and articles made therefrom
US5470967A (en) * 1990-04-10 1995-11-28 The Dupont Merck Pharmaceutical Company Oligonucleotide analogs with sulfamate linkages
US5643780A (en) * 1992-04-03 1997-07-01 Isis Pharmaceuticals, Inc. Compositions and methods for modulating RNA activity through modification of the 5' cap structure of RNA
US5653472A (en) * 1995-07-25 1997-08-05 The Standard Register Company Form having detachable wristband and labels
AU7360198A (en) * 1997-04-22 1998-11-13 Life Technologies, Inc. Methods for the production of aslv reverse transcriptases composed of multiple subunits
US7386949B2 (en) * 1997-10-14 2008-06-17 Laser Band, Llc Special precautions self-laminating wristband business form and method
US7047682B2 (en) * 2002-09-27 2006-05-23 Laser Band, Llc Wristband/label assembly business form and method
US6000160A (en) * 1997-10-14 1999-12-14 Riley; James M. Computer generated moisture proof identification bracelet
US6510634B1 (en) * 1997-10-14 2003-01-28 Laser Band, Llc Multiple computer generated multi-web moisture proof identification bracelets on a single form with window
US7017293B2 (en) * 2002-09-27 2006-03-28 Laser Band, Llc Wristband/cinch with label assembly business form and method
US7017294B2 (en) * 2002-09-27 2006-03-28 Laser Band, Llc Wristband/cinch with inboard label assembly business form and method
US6016618A (en) * 1997-11-17 2000-01-25 Avery Dennison Corporation Laminated article
WO2001029249A2 (en) 1999-10-15 2001-04-26 Yale University Conjoined polynucleotide catalysts
US20040261644A1 (en) * 2001-09-14 2004-12-30 Stewart Thomas R. Medical patient labeling system and method
US6788687B2 (en) * 2001-10-30 2004-09-07 Qualcomm Incorporated Method and apparatus for scheduling packet data transmissions in a wireless communication system
US6836215B1 (en) * 2002-01-22 2004-12-28 The Standard Register Company Printable identification band with top strip for RFID chip attachment
US7316358B2 (en) * 2002-03-18 2008-01-08 Precision Dynamics Corporation Identification band with adhesively attached coupling elements
US7074596B2 (en) * 2002-03-25 2006-07-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthesis and use of anti-reverse mRNA cap analogues
US7000951B2 (en) * 2002-09-13 2006-02-21 Chicago Tag And Label, Inc. Form having a removable wristband and labels
US6971200B2 (en) * 2002-09-13 2005-12-06 Chicago Tag & Label Form having a removable wristband and labels
US7520077B2 (en) * 2004-06-17 2009-04-21 Laser Band, Llc Cushioned wristband with self-laminating identity tag
US20050181165A1 (en) * 2002-11-13 2005-08-18 Franko Joseph D.Sr. Glue-applied resealable expanded content label
US7322613B2 (en) * 2002-12-17 2008-01-29 Precision Dynamic, Corporation Multi-part form having detachable wristband, labels and cards or the like
US7222748B2 (en) * 2003-09-26 2007-05-29 Royal Vendors, Inc. Clear door vending machine
US20050091896A1 (en) * 2003-10-30 2005-05-05 Kotik Mark M. Identification band with detachable machine-readable lables
US7320194B2 (en) * 2004-06-01 2008-01-22 Precision Dynamics Corporation Adhesive wristband without removable release liner
US7658026B2 (en) * 2006-10-27 2010-02-09 Laser Band, Llc Wristband with snap closure and patent id label
US20050285385A1 (en) * 2004-06-28 2005-12-29 Bova Antonio V Emergency medical analysis form with detachable patient identification piece and method of using same
US7417541B2 (en) * 2004-10-08 2008-08-26 Bartronics America, Inc. Identification band with regions having electro-magnetically detectable regions
US20060113788A1 (en) * 2004-11-30 2006-06-01 Laser Band, Llc. Laser printable business form having a self laminating wristband and a self laminating strip label
US7810267B2 (en) * 2005-04-21 2010-10-12 Avery Dennison Corporation Patient identification products
US20070120358A1 (en) * 2005-11-30 2007-05-31 Waggoner Bryce C Patient wristband form
US20070283607A1 (en) * 2006-06-13 2007-12-13 Printmark Industries, Inc. Printed identification band and method of manufacturing same
US20080067802A1 (en) * 2006-08-24 2008-03-20 Tri-State Hospital Supply Corporation Self-laminating label for a wristband
US8424115B2 (en) * 2006-10-27 2013-04-23 Laser Band, Llc Wristband with contoured comfort sides
US7946065B2 (en) * 2007-06-14 2011-05-24 Precision Dynamics Corporation Closure mechanism for an identification medium adapted for receiving indicia forming material and dual closure means

Also Published As

Publication number Publication date
CA2692906C (en) 2016-01-19
US20100233757A1 (en) 2010-09-16
EP2167523B1 (en) 2014-07-23
CN101855231A (zh) 2010-10-06
CN107501370B (zh) 2021-06-18
WO2008157688A3 (en) 2009-02-26
PT2167523E (pt) 2014-09-22
EA017740B1 (ru) 2013-02-28
CN101855231B (zh) 2014-06-11
EP2167523A4 (en) 2011-06-15
EA201070030A1 (ru) 2010-06-30
EP2167523A2 (en) 2010-03-31
CN107501370A (zh) 2017-12-22
ES2500515T3 (es) 2014-09-30
HRP20140771T1 (hr) 2014-11-07
HK1200461A1 (en) 2015-08-07
CN104072561A (zh) 2014-10-01
SI2167523T1 (sl) 2014-09-30
AU2008265683B2 (en) 2013-08-29
CA2692906A1 (en) 2008-12-24
US8153773B2 (en) 2012-04-10
PL2167523T3 (pl) 2014-12-31
CN104072561B (zh) 2017-12-22
AU2008265683A1 (en) 2008-12-24
WO2008157688A2 (en) 2008-12-24
DK2167523T3 (da) 2014-09-08

Similar Documents

Publication Publication Date Title
CY1115525T1 (el) Συνθεση και χρηση αντι-αντιστροφων φωσφοροθειοϊκων αναλογων της καλυπτρας αγγελιοφορου rna
Zhu et al. ASH1L links histone H3 lysine 36 dimethylation to MLL leukemia
Zatsepin et al. Synthesis of peptide− oligonucleotide conjugates with single and multiple peptides attached to 2 ‘-aldehydes through thiazolidine, oxime, and hydrazine linkages
ES2967788T3 (es) Expresión especifica de célula de Arnmond
CY1119046T1 (el) Μεσα κυτταροκαλλιεργειας χωρις ολιγοπεπτιδια
Viol et al. Nek2 kinase displaces distal appendages from the mother centriole prior to mitosis
CY1117161T1 (el) Βελτιωμενοι κυτταροτοξικοι παραγοντες οι οποιοι περιεχουν νεα μεϋτανσινοειδη
BRPI0409911A (pt) método para liberar uma molécula em uma célula, e, complexo carreador
MX2008014100A (es) Compuestos y metodos para modular la expresion de pcsk9.
Stimpfel et al. New challenge: mitochondrial epigenetics?
MX2007008980A (es) Acidos nucleicos para apoptosis de celulas cancerigenas.
BRPI0518580A2 (pt) mÉtodo para melhorar a depuraÇço hepÁtica de substÂncias xenobiàticas em um animal, kit adequado para alimentar Ácido lipàico a um animal, meio para comunicar informaÇço, composiÇço, e, uso da composiÇço que compreende Ácido lipàico
ATE387915T1 (de) Neue klinische parameter zur bestimmung einer hämatologischen toxizität vor einer strahlenimmuntherapie
BRPI0518579A2 (pt) mÉtodo para aumentar a atividade de cÉlula exterminadora natural em um animal, kit adequado para alimentar Ácido lipàico a um animal, meio para comunicar informaÇço, composiÇço, uso da composiÇço que compreende Ácido lipàico, e, mÉtodo para aumentar a resposta imune em um animal
ATE408398T1 (de) Nanopartikele für dna verabreichung zu einem zielorgan
CY1106693T1 (el) Πελετες οι οποιες περιεχουν υδροχλωρικη βενλαφαξινη
JP2020537540A5 (el)
BR112013017002A2 (pt) "proteínas mic não naturais, seu uso no tratamento de malignalidade ou infecção viral, bem como composição compreendendo as referidas proteínas"
Shanak et al. DNA methylation and the core pluripotency network
SG10201407944TA (en) Imp-3 oligopeptides and vaccines including the same
DK1722835T3 (da) Hyaluronsyre-derivatbaseret tredimensional matrix
JP2020515287A5 (el)
JP5676140B2 (ja) ヒト癌化細胞の作製方法
WO2003099228A8 (en) Compositions and processes for inhibiting gene expression using polynucleotides
WO2007016580A3 (en) Silencing rna molecules and their use in bone formation